Your browser is no longer supported. Please, upgrade your browser.
Settings
ATHE Alterity Therapeutics Limited daily Stock Chart
ATHE [NASD]
Alterity Therapeutics Limited
Index- P/E- EPS (ttm)-0.69 Insider Own18.70% Shs Outstand14.47M Perf Week-13.13%
Market Cap28.80M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float9.96M Perf Month118.54%
Income-8.80M PEG- EPS next Q- Inst Own2.10% Short Float0.07% Perf Quarter120.63%
Sales- P/S- EPS this Y-29.30% Inst Trans- Short Ratio0.00 Perf Half Y69.51%
Book/sh0.54 P/B2.57 EPS next Y- ROA-75.20% Target Price- Perf Year16.81%
Cash/sh- P/C- EPS next 5Y- ROE-92.30% 52W Range0.28 - 2.35 Perf YTD78.21%
Dividend- P/FCF- EPS past 5Y8.40% ROI- 52W High-40.85% Beta1.13
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low396.43% ATR0.18
Employees15 Current Ratio4.40 Sales Q/Q-23.50% Oper. Margin- RSI (14)66.26 Volatility8.36% 12.08%
OptionableNo Debt/Eq0.00 EPS Q/Q4.10% Profit Margin- Rel Volume0.10 Prev Close1.43
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.98M Price1.39
Recom- SMA2051.21% SMA5087.64% SMA20071.20% Volume190,933 Change-2.80%
Jul-01-20 08:12AM  
Jun-29-20 11:14PM  
May-20-20 08:58PM  
Apr-30-20 04:35AM  
Apr-21-20 05:50PM  
Feb-21-20 07:15PM  
Nov-11-19 10:30PM  
Sep-12-19 11:07PM  
Jul-29-19 08:00AM  
Jul-11-19 09:31PM  
May-06-19 08:00AM  
May-03-19 08:00AM  
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment of Parkinson's disease and other movement disorders. It is also developing PBT2 for patients with Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.